Welcome to our dedicated page for Exelixis news (Ticker: EXEL), a resource for investors and traders seeking the latest updates and insights on Exelixis stock.
Exelixis Inc (EXEL) is a leading biopharmaceutical company focused on developing innovative cancer therapies through cutting-edge small molecule research. This page serves as a comprehensive resource for all official company updates and oncology-related developments.
Access timely EXEL news including FDA approvals, clinical trial results, and strategic partnerships with global pharmaceutical leaders. Investors will find essential updates on earnings reports, research milestones, and therapy commercialization efforts that demonstrate the company's progress in oncology treatment innovation.
Our curated news collection provides verified information about EXEL's drug development pipeline, regulatory achievements, and collaborative research initiatives. The content is maintained to support informed analysis of the company's market position and scientific advancements in cancer care.
Bookmark this page for direct access to Exelixis' latest press releases and objective reporting on their contributions to targeted cancer therapies. Check regularly for updates reflecting the company's ongoing work in transforming oncology treatment paradigms.
Exelixis, Inc. (Nasdaq: EXEL) will participate in fireside chats at investor conferences in May, including BofA Securities Health Care Conference, Citizens JMP Life Sciences Conference, and RBC Capital Markets Global Healthcare Conference. The presentations will be webcast on www.exelixis.com with replay options available for at least 30 days.
Exelixis, Inc. (Nasdaq: EXEL) reported Q1 2024 financial results of $425M in total revenues, $379M from Cabozantinib Franchise U.S. Net Product Revenues. Restructuring expenses of $32.8M were recorded. GAAP Diluted EPS was $0.12, Non-GAAP Diluted EPS was $0.17. Exelixis focused on advancing pivotal trials, pipeline development, and label expansion for cabozantinib. The company maintained financial guidance for 2024. Positive clinical trial results were highlighted, and strategic priorities for 2024 were outlined. Exelixis also announced share repurchase program updates and key board member appointments.
